Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | MicrobiomeTrials← Back to trialsNCT02508038
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2016-02-12Est. Completion: 2026-12
Enrollment target: 22 participants Locations- University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Other microbiome trials you might be interested in
Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX7…
Tucson, United StatesEst. completion Mar 31, 2027
B Acute Lymphoblastic Leukemia
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemothe…
Birmingham, United StatesEst. completion Dec 1, 2030
Accelerated Phase Myeloproliferative NeoplasmBlast Phase Myeloproliferative NeoplasmEssential ThrombocythemiaMyelodysplastic/Myeloproliferative NeoplasmMyeloproliferative Neoplasm, Not Otherwise SpecifiedPolycythemia VeraPrimary MyelofibrosisSecondary Myelofibrosis
This phase II trial compares the effect of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients…
Irvine, United StatesEst. completion Dec 31, 2027